{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:21:05Z","timestamp":1793042465321,"version":"4.5.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12035-025-04762-3","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:51:19Z","timestamp":1740030679000},"page":"8103-8120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Emodin, a Potent Anthraquinone Mitigates MPTP-Induced Parkinsons\u2019 Disease Pathology by Regulating Nrf2 and Its Downstream Targets: In Silico and In Vivo Approach"],"prefix":"10.1007","volume":"62","author":[{"given":"Sarwat","family":"Jahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Siraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakir","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Zakria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"issue":"8","key":"4762_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.11477\/mf.1416201365","volume":"71","author":"M Kawamura","year":"2019","unstructured":"Kawamura M, Okamoto T, Kikuchi R (2019) From \u201cshaking palsy\u201d to \u201cParkinson\u2019s disease\u201d: was Charcot correct? Brain Nerve 71(8):847\u2013855. https:\/\/doi.org\/10.11477\/mf.1416201365","journal-title":"Brain Nerve"},{"key":"4762_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.parkreldis.2017.07.019","volume":"46","author":"S Fahn","year":"2018","unstructured":"Fahn S (2018) The 200-year journey of Parkinson disease: reflecting on the past and looking towards the future. Parkinsonism Relat Disord 46:S1\u2013S5. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.07.019","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"4762_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/ageing\/afx192","volume":"47","author":"C McDonald","year":"2018","unstructured":"McDonald C, Gordon G, Hand A, Walker RW, Fisher JM (2018) 200 years of Parkinson\u2019s disease: what have we learnt from James Parkinson? Age Ageing 47(2):209\u2013214. https:\/\/doi.org\/10.1093\/ageing\/afx192","journal-title":"Age Ageing"},{"key":"4762_CR4","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s12264-017-0178-2","volume":"33","author":"S Li","year":"2017","unstructured":"Li S, Le W (2017) Milestones of Parkinson\u2019s disease research: 200 years of history and beyond. Neurosci Bull 33:598\u2013602. https:\/\/doi.org\/10.1007\/s12264-017-0178-2","journal-title":"Neurosci Bull"},{"key":"4762_CR5","doi-asserted-by":"publisher","first-page":"105687","DOI":"10.1016\/j.neuro.2024.04.005","volume":"168","author":"MX Henderson","year":"2022","unstructured":"Henderson MX, Henrich MT, Geibl FF, Oertel WH, Brundin P, Surmeier DJ (2022) The roles of connectivity and neuronal phenotype in determining the pattern of \u03b1-synuclein pathology in Parkinson\u2019s disease. Neurobiol Dis 168:105687. https:\/\/doi.org\/10.1016\/j.neuro.2024.04.005","journal-title":"Neurobiol Dis"},{"key":"4762_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/S10571-021-01066-7","volume":"42","author":"N Dogra","year":"2022","unstructured":"Dogra N, Mani RJ, Katare DP (2022) The gut-brain axis: two ways signaling in Parkinson\u2019s disease. Cell Mol Neurobiol 42:315\u2013332. https:\/\/doi.org\/10.1007\/S10571-021-01066-7","journal-title":"Cell Mol Neurobiol"},{"key":"4762_CR7","doi-asserted-by":"publisher","first-page":"736978","DOI":"10.3389\/fmed.2021.736978","volume":"8","author":"E Srinivasan","year":"2021","unstructured":"Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram AS, Karunakaran R, Rajasekaran R, Srikumar PS (2021) Alpha-synuclein aggregation in Parkinson\u2019s disease. Front Med 8:736978. https:\/\/doi.org\/10.3389\/fmed.2021.736978","journal-title":"Front Med"},{"key":"4762_CR8","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s44321-024-00083-5","volume":"10","author":"L De Boni","year":"2024","unstructured":"De Boni L, Wallis A, Watson AH et al (2024) Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson\u2019s patients. EMBO J 10:1657\u20131674. https:\/\/doi.org\/10.1038\/s44321-024-00083-5","journal-title":"EMBO J"},{"key":"4762_CR9","doi-asserted-by":"publisher","unstructured":"G\u00f3mez-Benito M, Granado N, Garc\u00eda-Sanz P et al (2020) Modeling Parkinson\u2019s disease with the alpha-synuclein protein. Front Pharmacol 11. https:\/\/doi.org\/10.3389\/FPHAR.2020.00356\/FULL","DOI":"10.3389\/FPHAR.2020.00356\/FULL"},{"key":"4762_CR10","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"B Bloem","year":"2021","unstructured":"Bloem B, Okun M, Lancet CK-T (2021) Parkinson\u2019s disease. Lancet 397:2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)00218-X","journal-title":"Lancet"},{"key":"4762_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ENE.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV (2020) Parkinson disease. Eur J Neurol 27:27\u201342. https:\/\/doi.org\/10.1111\/ENE.14108","journal-title":"Eur J Neurol"},{"key":"4762_CR12","doi-asserted-by":"publisher","unstructured":"Ou Z, Pan J, Tang S et al (2021) Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s disease in 204 countries\/territories from 1990 to 2019. Front Public Health 9. https:\/\/doi.org\/10.3389\/FPUBH.2021.776847\/FULL","DOI":"10.3389\/FPUBH.2021.776847\/FULL"},{"issue":"1","key":"4762_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.09.001","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36(1):1\u20132. https:\/\/doi.org\/10.1016\/j.cger.2019.09.001","journal-title":"Clin Geriatr Med"},{"key":"4762_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Y Ben-Shlomo","year":"2024","unstructured":"Ben-Shlomo Y, Darweesh SKL, Llibre-Guerra J et al (2024) The epidemiology of Parkinson\u2019s disease. Lancet 403:283\u2013292. https:\/\/doi.org\/10.1016\/S0140-6736(23)01419-8","journal-title":"Lancet"},{"key":"4762_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J (2020) Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Psychiatr 91:795\u2013808. https:\/\/doi.org\/10.1136\/jnnp-2019-322338","journal-title":"J Neurol Psychiatr"},{"key":"4762_CR16","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1007\/S00415-020-09863-8","volume":"268","author":"E Sarasso","year":"2021","unstructured":"Sarasso E, Agosta F, Piramide N, Filippi M (2021) Progression of grey and white matter brain damage in Parkinson\u2019s disease: a critical review of structural MRI literature. J Neurol 268:3144\u20133179. https:\/\/doi.org\/10.1007\/S00415-020-09863-8","journal-title":"J Neurol"},{"key":"4762_CR17","doi-asserted-by":"publisher","unstructured":"Verma M, Lizama B (2022) Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Neurodegener Dis 11. https:\/\/doi.org\/10.1186\/s40035-021-00278-7","DOI":"10.1186\/s40035-021-00278-7"},{"issue":"10","key":"4762_CR18","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1093\/brain\/awad291","volume":"147","author":"C Roodveldt","year":"2024","unstructured":"Roodveldt C, Bernardino L, Oztop-Cakmak O, Dragic M, Fladmark KE, Ertan S, Aktas B, Pita C, Ciglar L, Garraux G, Williams-Gray C (2024) The immune system in Parkinson\u2019s disease: what we know so far. Brain 147(10):3306\u20133324. https:\/\/doi.org\/10.1093\/brain\/awad291","journal-title":"Brain"},{"key":"4762_CR19","doi-asserted-by":"publisher","unstructured":"Hadi F, Mortaja M, Hadi Z (2024) Calcium (Ca2+) hemostasis, mitochondria, autophagy, and mitophagy contribute to Alzheimer\u2019s disease as early moderators. Cell Biochem Funct 42(5). https:\/\/doi.org\/10.1002\/cbf.4085","DOI":"10.1002\/cbf.4085"},{"issue":"9","key":"4762_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2174\/1389557520666200420104213","volume":"20","author":"BL Marino","year":"2020","unstructured":"Marino BL, de Souza LR, Sousa KP, Ferreira JV, Padilha EC, da Silva CH, Taft CA, Hage-Melim LI (2020) Parkinson\u2019s disease: a review from pathophysiology to treatment. Mini Rev Med Chem 20(9):754\u2013767. https:\/\/doi.org\/10.2174\/1389557520666200420104213","journal-title":"Mini Rev Med Chem"},{"key":"4762_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/S11011-021-00689-5","volume":"36","author":"V Zaman","year":"2021","unstructured":"Zaman V, Shields DC, Shams R et al (2021) Cellular and molecular pathophysiology in the progression of Parkinson\u2019s disease. Metab Brain Dis 36:815\u2013827. https:\/\/doi.org\/10.1007\/S11011-021-00689-5","journal-title":"Metab Brain Dis"},{"key":"4762_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/ANNUREV-NEURO-100720-034518","volume":"44","author":"GE V\u00e1zquez-V\u00e9lez","year":"2021","unstructured":"V\u00e1zquez-V\u00e9lez GE, Zoghbi HY (2021) Parkinson\u2019s disease genetics and pathophysiology. Annu Rev Neurosci 44:87\u2013108. https:\/\/doi.org\/10.1146\/ANNUREV-NEURO-100720-034518","journal-title":"Annu Rev Neurosci"},{"key":"4762_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/MDS.28826","volume":"37","author":"S Charisis","year":"2022","unstructured":"Charisis S, Ntanasi E, Stamelou M et al (2022) Plasma glutathione and prodromal Parkinson\u2019s disease probability. Mov Disord 37:200\u2013205. https:\/\/doi.org\/10.1002\/MDS.28826","journal-title":"Mov Disord"},{"issue":"7","key":"4762_CR24","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3390\/antiox12071445","volume":"12","author":"C Di Giacomo","year":"2023","unstructured":"Di Giacomo C, Malfa GA, Tomasello B, Bianchi S, Acquaviva R (2023) Natural compounds and glutathione: beyond mere antioxidants. Antioxidants 12(7):1445. https:\/\/doi.org\/10.3390\/antiox12071445","journal-title":"Antioxidants"},{"key":"4762_CR25","doi-asserted-by":"publisher","unstructured":"Wang J, Wang F, Mai D, Qu S (2020) Molecular mechanisms of glutamate toxicity in Parkinson\u2019s disease. Front Neurosci 14. https:\/\/doi.org\/10.3389\/FNINS.2020.585584\/FULL","DOI":"10.3389\/FNINS.2020.585584\/FULL"},{"key":"4762_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.3073","author":"C Niu","year":"2024","unstructured":"Niu C, Dong M, Niu Y (2024) Role of glutathione in Parkinson\u2019s disease pathophysiology and therapeutic potential of polyphenols. Phytother Res. https:\/\/doi.org\/10.1002\/ptr.3073","journal-title":"Phytother Res"},{"key":"4762_CR27","doi-asserted-by":"publisher","unstructured":"Ganguly U, Singh S, Pal S et al (2021) Alpha-synuclein as a biomarker of Parkinson\u2019s disease: good, but not good enough. Front Aging Neurosci 13. https:\/\/doi.org\/10.3389\/FNAGI.2021.702639\/FULL","DOI":"10.3389\/FNAGI.2021.702639\/FULL"},{"issue":"10423","key":"4762_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01291-4","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH (2024) The pathogenesis of Parkinson\u2019s disease. Lancet 403(10423):293\u2013304. https:\/\/doi.org\/10.1016\/S0140-6736(23)01291-4","journal-title":"Lancet"},{"key":"4762_CR29","doi-asserted-by":"publisher","first-page":"787258","DOI":"10.3389\/fncel.2021.787258","volume":"1","author":"U Gomez-Pinedo","year":"2022","unstructured":"Gomez-Pinedo U, Del A, Sanz P et al (2022) A perspective on Nrf2 signaling pathway for neuroinflammation: a potential therapeutic target in Alzheimer\u2019s and Parkinson\u2019s diseases. Front Cell Neurosci 1:787258. https:\/\/doi.org\/10.3389\/fncel.2021.787258","journal-title":"Front Cell Neurosci"},{"key":"4762_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/S00109-021-02071-5","volume":"99","author":"Y Niu","year":"2021","unstructured":"Niu Y, Zhang J, Dong M (2021) Nrf2 as a potential target for Parkinson\u2019s disease therapy. J Mol Med 99:917\u2013931. https:\/\/doi.org\/10.1007\/S00109-021-02071-5","journal-title":"J Mol Med"},{"key":"4762_CR31","doi-asserted-by":"publisher","unstructured":"Yang XX, Yang R, Zhang F (2022) Role of Nrf2 in Parkinson\u2019s disease: toward new perspectives. Front Pharmacol 13. https:\/\/doi.org\/10.3389\/FPHAR.2022.919233\/FULL","DOI":"10.3389\/FPHAR.2022.919233\/FULL"},{"key":"4762_CR32","doi-asserted-by":"publisher","unstructured":"Saha S, Buttari B, Profumo E et al (2022) A perspective on Nrf2 signaling pathway for neuroinflammation: a potential therapeutic target in Alzheimer\u2019s and Parkinson\u2019s diseases. Front Cell Neurosci 15. https:\/\/doi.org\/10.3389\/FNCEL.2021.787258\/FULL","DOI":"10.3389\/FNCEL.2021.787258\/FULL"},{"key":"4762_CR33","doi-asserted-by":"publisher","first-page":"115496","DOI":"10.1016\/j.bcp.2023.115496","volume":"210","author":"SS Khan","year":"2023","unstructured":"Khan SS, Janrao S, Srivastava S, Singh SB, Vora L, Khatri DK (2023) GSK-3\u03b2: an exuberating neuroinflammatory mediator in Parkinson\u2019s disease. Biochem Pharmacol 210:115496. https:\/\/doi.org\/10.1016\/j.bcp.2023.115496","journal-title":"Biochem Pharmacol"},{"key":"4762_CR34","doi-asserted-by":"publisher","first-page":"101915","DOI":"10.1016\/j.arr.2023.101915","volume":"87","author":"S Rajan","year":"2023","unstructured":"Rajan S, Tryphena KP, Khan S, Vora L, Srivastava S, Singh SB, Khatri DK (2023) Understanding the involvement of innate immunity and the Nrf2-NLRP3 axis on mitochondrial health in Parkinson\u2019s disease. Ageing Res Rev 87:101915. https:\/\/doi.org\/10.1016\/j.arr.2023.101915","journal-title":"Ageing Res Rev"},{"issue":"8","key":"4762_CR35","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1021\/acschemneuro.3c00049","volume":"14","author":"KP Tryphena","year":"2023","unstructured":"Tryphena KP, Nikhil US, Pinjala P, Srivastava S, Singh SB, Khatri DK (2023) Mitochondrial complex I as a pathologic and therapeutic target for Parkinson\u2019s disease. ACS Chem Neurosci 14(8):1356\u20131368. https:\/\/doi.org\/10.1021\/acschemneuro.3c00049","journal-title":"ACS Chem Neurosci"},{"key":"4762_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40035-023-00300-w","volume":"12","author":"P Naren","year":"2023","unstructured":"Naren P, Samim KS, Tryphena KP (2023) Microtubule acetylation dyshomeostasis in Parkinson\u2019s disease. Transl Neurodegener 12:20. https:\/\/doi.org\/10.1186\/s40035-023-00300-w","journal-title":"Transl Neurodegener"},{"key":"4762_CR37","doi-asserted-by":"publisher","first-page":"111826","DOI":"10.1016\/j.mad.2023.111826","volume":"213","author":"SN Uppala","year":"2023","unstructured":"Uppala SN, Tryphena KP, Naren P, Srivastava S, Singh SB, Khatri DK (2023) Involvement of miRNA on epigenetics landscape of Parkinson\u2019s disease: from pathogenesis to therapeutics. Mech Ageing Dev 213:111826. https:\/\/doi.org\/10.1016\/j.mad.2023.111826","journal-title":"Mech Ageing Dev"},{"key":"4762_CR38","doi-asserted-by":"publisher","unstructured":"Yu C, Longevity JX-OM, C (2021) The Keap1\u2010Nrf2 system: a mediator between oxidative stress and aging. Wiley Online Library 2021. https:\/\/doi.org\/10.1155\/2021\/6635460","DOI":"10.1155\/2021\/6635460"},{"key":"4762_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.freeradbiomed.2021.12.003","volume":"179","author":"QM Chen","year":"2022","unstructured":"Chen QM (2022) Nrf2 for protection against oxidant generation and mitochondrial damage in cardiac injury. Free Radic Biol Med 179:133\u2013143. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.12.003","journal-title":"Free Radic Biol Med"},{"key":"4762_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117329","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Ahmadi Z, Samarghandian S et al (2020) MicroRNA-mediated regulation of Nrf2 signaling pathway: implications in disease therapy and protection against oxidative stress. Elsevier. https:\/\/doi.org\/10.1016\/j.lfs.2020.117329","journal-title":"Elsevier"},{"issue":"2","key":"4762_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1573406220666200127110033","volume":"20","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Ahmadi Z, Mohammadinejad R, Farkhondeh T, Samarghandian S (2020) Curcumin activates the Nrf2 pathway and induces cellular protection against oxidative injury. Curr Mol Med 20(2):116\u2013133. https:\/\/doi.org\/10.2174\/1573406220666200127110033","journal-title":"Curr Mol Med"},{"key":"4762_CR42","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1002\/JCP.29219","volume":"235","author":"P Shaw","year":"2020","unstructured":"Shaw P, Chattopadhyay A (2020) Nrf2\u2013ARE signaling in cellular protection: mechanism of action and the regulatory mechanisms. J Cell Physiol 235:3119\u20133130. https:\/\/doi.org\/10.1002\/JCP.29219","journal-title":"J Cell Physiol"},{"key":"4762_CR43","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/biom10020320","volume":"10","author":"S Kasai","year":"2020","unstructured":"Kasai S, Shimizu S, Tatara Y et al (2020) Regulation of Nrf2 by mitochondrial reactive oxygen species in physiology and pathology. Biomolecules 10:320. https:\/\/doi.org\/10.3390\/biom10020320","journal-title":"Biomolecules"},{"key":"4762_CR44","doi-asserted-by":"publisher","unstructured":"Bono S, Feligioni M, Neurodegeneration MC-M (2021) Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy. Springer 16. https:\/\/doi.org\/10.1186\/s13024-021-00479-8","DOI":"10.1186\/s13024-021-00479-8"},{"key":"4762_CR45","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1111\/febs.16336","volume":"289","author":"RG Bardallo","year":"2022","unstructured":"Bardallo RG, Panisello-Rosell OA, Sanchez-Nuno S et al (2022) Nrf2 and oxidative stress in liver ischemia\/reperfusion injury. FEBS J 289:5463\u20135479. https:\/\/doi.org\/10.1111\/febs.16336","journal-title":"FEBS J"},{"key":"4762_CR46","doi-asserted-by":"crossref","unstructured":"Gong Y, sciences YY-L (2020) Activation of Nrf2\/AREs-mediated antioxidant signaling, and suppression of profibrotic TGF-\u03b21\/Smad3 pathway: a promising therapeutic strategy for hepatic fibrosis. Elsevier","DOI":"10.1016\/j.lfs.2020.117909"},{"key":"4762_CR47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/17512433.2021.1901578","volume":"14","author":"M Egbujor","year":"2021","unstructured":"Egbujor M, Saha S, Buttari B et al (2021) Activation of Nrf2 signaling pathway by natural and synthetic chalcones: a therapeutic road map for oxidative stress. Taylor & Francis 14:465\u2013480. https:\/\/doi.org\/10.1080\/17512433.2021.1901578","journal-title":"Taylor & Francis"},{"issue":"13","key":"4762_CR48","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1089\/ars.2023.0234","volume":"38","author":"A Uruno","year":"2023","unstructured":"Uruno A, Yamamoto M (2023) The KEAP1-NRF2 system and neurodegenerative diseases. Antioxid Redox Signal 38(13):974\u2013988. https:\/\/doi.org\/10.1089\/ars.2023.0234","journal-title":"Antioxid Redox Signal"},{"key":"4762_CR49","doi-asserted-by":"crossref","unstructured":"Amoroso R, Maccallini C, Antioxidants IB-. (2023) Activators of Nrf2 to counteract neurodegenerative diseases. MDPI","DOI":"10.3390\/antiox12030778"},{"key":"4762_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/ANNUREV-PHARMTOX-052220-103416","volume":"62","author":"A Cuadrado","year":"2022","unstructured":"Cuadrado A (2022) Brain-protective mechanisms of transcription factor NRF2: toward a common strategy for neurodegenerative diseases. Annu Rev Pharmacol Toxicol 62:255\u2013277. https:\/\/doi.org\/10.1146\/ANNUREV-PHARMTOX-052220-103416","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4762_CR51","doi-asserted-by":"publisher","unstructured":"Zgorzynska E, Dziedzic B, of AW-IJ (2021) An overview of the Nrf2\/ARE pathway and its role in neurodegenerative diseases. MDPI. https:\/\/doi.org\/10.3390\/ijms22179592","DOI":"10.3390\/ijms22179592"},{"key":"4762_CR52","doi-asserted-by":"publisher","first-page":"115998","DOI":"10.1016\/j.ejmech.2023.115998","volume":"251","author":"J Wang","year":"2023","unstructured":"Wang J, Cao Y, Lu Y, Zhu H, Zhang J, Che J, Zhuang R, Shao J (2023) Recent progress and applications of small molecule inhibitors of Keap1\u2013Nrf2 axis for neurodegenerative diseases. Eur J Med Chem 251:115998. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115998","journal-title":"Eur J Med Chem"},{"key":"4762_CR53","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/S12640-023-00647-2","volume":"41","author":"SV Mangrulkar","year":"2023","unstructured":"Mangrulkar SV, Wankhede NL, Kale MB et al (2023) Mitochondrial dysfunction as a signaling target for therapeutic intervention in major neurodegenerative disease. Neurotox Res 41:708\u2013729. https:\/\/doi.org\/10.1007\/S12640-023-00647-2","journal-title":"Neurotox Res"},{"issue":"6","key":"4762_CR54","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/biom10060904","volume":"10","author":"\u00c1 Cores","year":"2021","unstructured":"Cores \u00c1, Piquero M, Villacampa M et al (2021) NRF2 regulation processes as a source of potential drug targets against neurodegenerative diseases. Biomolecules 10(6):904. https:\/\/doi.org\/10.3390\/biom10060904","journal-title":"Biomolecules"},{"key":"4762_CR55","doi-asserted-by":"publisher","unstructured":"Bose C, Alves I, Singh P et al (2020) The Keap1\u2010Nrf2 system: a mediator between oxidative stress and aging. Antioxidants 19. https:\/\/doi.org\/10.1111\/acel.13261","DOI":"10.1111\/acel.13261"},{"key":"4762_CR56","doi-asserted-by":"publisher","unstructured":"Yu C, Xiao JH (2021) The Keap1-Nrf2 system: a mediator between oxidative stress and aging. Oxid Med Cell Longev 2021. https:\/\/doi.org\/10.1155\/2021\/6635460","DOI":"10.1155\/2021\/6635460"},{"key":"4762_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11010008","author":"S Boas","year":"2021","unstructured":"Boas S, Joyce K, Antioxidants RC (2021) The NRF2-dependent transcriptional regulation of antioxidant defense pathways: relevance for cell type-specific vulnerability to neurodegeneration and therapeutic. MDPI. https:\/\/doi.org\/10.3390\/antiox11010008","journal-title":"MDPI"},{"key":"4762_CR58","doi-asserted-by":"publisher","unstructured":"K\u00fcpeli Akkol E, Tatl\u0131 \u00c7ankaya I, \u015eeker Karatoprak G et al (2021) Natural compounds as medical strategies in the prevention and treatment of psychiatric disorders seen in neurological diseases. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/FPHAR.2021.669638\/FULL","DOI":"10.3389\/FPHAR.2021.669638\/FULL"},{"key":"4762_CR59","doi-asserted-by":"publisher","unstructured":"Shafika N, Sairazi M, Sirajudeen KNS (2020) Natural products and their bioactive compounds: neuroprotective potentials against neurodegenerative diseases. Wiley Online Library 2020. https:\/\/doi.org\/10.1155\/2020\/6565396","DOI":"10.1155\/2020\/6565396"},{"key":"4762_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/molecules","author":"D Berillo","year":"2022","unstructured":"Berillo D, Kozhahmetova M (2022) Overview of the biological activity of anthraquinones and flavonoids of the plant rumex species. Molecules. https:\/\/doi.org\/10.3390\/molecules","journal-title":"Molecules"},{"key":"4762_CR61","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/jps.21978","volume":"99","author":"C-S Shia","year":"2009","unstructured":"Shia C-S, Hou Y-C, Tsai S-Y et al (2009) Differences in pharmacokinetics and ex vivo antioxidant activity following intravenous and oral administrations of emodin to rats. Elsevier 99:2185\u20132195. https:\/\/doi.org\/10.1002\/jps.21978","journal-title":"Elsevier"},{"key":"4762_CR62","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/ptr.6532","volume":"34","author":"X Dong","year":"2019","unstructured":"Dong X, Zeng Y, Liu Y et al (2019) Aloe-emodin: a review of its pharmacology, toxicity, and pharmacokinetics. Wiley Online Library 34:270\u2013281. https:\/\/doi.org\/10.1002\/ptr.6532","journal-title":"Wiley Online Library"},{"key":"4762_CR63","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/00498254.2017.1382748","volume":"48","author":"J Yu","year":"2018","unstructured":"Yu J, Guo X, Zhang Q et al (2018) Metabolite profile analysis and pharmacokinetic study of emodin, baicalin and geniposide in rats. Xenobiotica 48:927\u2013937. https:\/\/doi.org\/10.1080\/00498254.2017.1382748","journal-title":"Xenobiotica"},{"key":"4762_CR64","volume-title":"Exploring the journey of emodin as a potential neuroprotective agent: novel therapeutic insights with molecular mechanism of action","author":"S Mitra","year":"2022","unstructured":"Mitra S, Anjum J, Muni M et al (2022) Exploring the journey of emodin as a potential neuroprotective agent: novel therapeutic insights with molecular mechanism of action. Elsevier"},{"key":"4762_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810578","author":"D Geun Hong","year":"2022","unstructured":"Geun Hong D, Lee S, Kim J et al (2022) Anti-inflammatory and neuroprotective effects of morin in an MPTP-induced Parkinson\u2019s disease model. MDPI. https:\/\/doi.org\/10.3390\/ijms231810578","journal-title":"MDPI"},{"key":"4762_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1451845","author":"E Bagwell","year":"2024","unstructured":"Bagwell E (2024) A review of MPTP-induced parkinsonism in adult zebrafish to explore pharmacological interventions for human Parkinson\u2019s disease. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2024.1451845","journal-title":"Front Neurosci"},{"key":"4762_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2024.105896","author":"JS Park","year":"2024","unstructured":"Park JS, Leem YH, Kim DY, Park JM, Kim SE, Kim HS (2024) Neuroprotective and anti-inflammatory effects of the RIPK3 inhibitor GSK872 in an MPTP-induced mouse model of Parkinson\u2019s disease. Neurochem Int. https:\/\/doi.org\/10.1016\/j.neuint.2024.105896","journal-title":"Neurochem Int"},{"key":"4762_CR68","doi-asserted-by":"publisher","unstructured":"Rosito M, Testi C, Parisi G et al (2020) Exploring the use of dimethyl fumarate as microglia modulator for neurodegenerative diseases treatment. MDPI. https:\/\/doi.org\/10.3390\/antiox9080700","DOI":"10.3390\/antiox9080700"},{"key":"4762_CR69","doi-asserted-by":"publisher","first-page":"175025","DOI":"10.1016\/j.ejphar.2022.175025","volume":"926","author":"I Majkutewicz","year":"2022","unstructured":"Majkutewicz I (2022) Dimethyl fumarate a review of preclinical efficacy in models of neurodegenerative diseases. Eur J Pharmacol 926:175025","journal-title":"Eur J Pharmacol"},{"key":"4762_CR70","doi-asserted-by":"crossref","unstructured":"Saha L, Singh N, Rawat K (2024) Neuroprotection induced by dimethyl fumarate. In: Natural molecules in neuroprotection and neurotoxicity pp. 1465\u20131486. Academic Press.","DOI":"10.1016\/B978-0-443-23763-8.00036-1"},{"key":"4762_CR71","doi-asserted-by":"crossref","unstructured":"Sivinski J, Zhang DD, Chapman E (2021) Targeting NRF2 to treat cancer. In: Seminars in Cancer Biology. 76:61\u201373. Academic Press.","DOI":"10.1016\/j.semcancer.2021.06.003"},{"key":"4762_CR72","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/164_2020_381","volume":"264","author":"D Lastra","year":"2021","unstructured":"Lastra D, Fern\u00e1ndez-Gin\u00e9s R, Manda G, Cuadrado A (2021) Perspectives on the clinical development of NRF2-targeting drugs. Handb Exp Pharmacol 264:93\u2013141. https:\/\/doi.org\/10.1007\/164_2020_381","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"4762_CR73","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3233\/JAD-230945","volume":"8","author":"P Pinjala","year":"2024","unstructured":"Pinjala P, Tryphena KP, Kulkarni A, Goswami PG, Khatri DK (2024) Dimethyl fumarate exerts a neuroprotective effect by enhancing mitophagy via the NRF2\/BNIP3\/PINK1 axis in the MPP+ iodide-induced Parkinson\u2019s disease mice model. J Alzheimer\u2019s Dis Rep 8(1):329\u2013344. https:\/\/doi.org\/10.3233\/JAD-230945","journal-title":"J Alzheimer\u2019s Dis Rep"},{"key":"4762_CR74","doi-asserted-by":"publisher","first-page":"148462","DOI":"10.1016\/j.brainres.2023.148462","volume":"1815","author":"M Khot","year":"2023","unstructured":"Khot M, Sood A, Tryphena KP, Pinjala P, Srivastava S, Singh SB, Khatri DK (2023) Dimethyl fumarate ameliorates parkinsonian pathology by modulating autophagy and apoptosis via Nrf2-TIGAR-LAMP2\/Cathepsin D axis. Brain Res 1815:148462. https:\/\/doi.org\/10.1016\/j.brainres.2023.148462","journal-title":"Brain Res"},{"issue":"1","key":"4762_CR75","doi-asserted-by":"publisher","first-page":"49","DOI":"10.17576\/jsm-2024-5301-05","volume":"53","author":"M Mustapha","year":"2024","unstructured":"Mustapha M, Taib CN, Fakurazi S, Moklas MA (2024) MPTP-induced BALB\/C mice recapitulate compensatory Parkinson\u2019s-like motor. Sains Malaysiana 53(1):49\u201361","journal-title":"Sains Malaysiana"},{"key":"4762_CR76","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/S11011-021-00840-2","volume":"36","author":"A Pathania","year":"2021","unstructured":"Pathania A, Garg P, Sandhir R (2021) Impaired mitochondrial functions and energy metabolism in MPTP-induced Parkinson\u2019s disease: comparison of mice strains and dose regimens. Metab Brain Dis 36:2343\u20132357. https:\/\/doi.org\/10.1007\/S11011-021-00840-2","journal-title":"Metab Brain Dis"},{"issue":"5","key":"4762_CR77","doi-asserted-by":"publisher","first-page":"101","DOI":"10.21315\/mjms2017.24.5.11","volume":"24","author":"WN Arifin","year":"2017","unstructured":"Arifin WN, Zahiruddin WM (2017) Sample size calculation in animal studies using resource equation approach. Malays J Med Sci 24(5):101","journal-title":"Malays J Med Sci"},{"issue":"1","key":"4762_CR78","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nprot.2006.342","volume":"2","author":"V Jackson-Lewis","year":"2007","unstructured":"Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson\u2019s disease. Nat Protoc 2(1):141\u2013151","journal-title":"Nat Protoc"},{"key":"4762_CR79","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jnc.15699","volume":"164","author":"M Santoro","year":"2023","unstructured":"Santoro M, Fadda P, Klephan KJ et al (2023) Neurochemical, histological, and behavioral profiling of the acute, sub-acute, and chronic MPTP mouse model of Parkinson\u02bcs disease. Wiley Online Library 164:121\u2013142. https:\/\/doi.org\/10.1111\/jnc.15699","journal-title":"Wiley Online Library"},{"key":"4762_CR80","doi-asserted-by":"publisher","first-page":"112877","DOI":"10.1016\/j.biopha.2022.112877","volume":"149","author":"S Mitra","year":"2022","unstructured":"Mitra S, Anjum J, Muni M, Das R, Rauf A, Islam F, Emran TB, Semwal P, Hemeg HA, Alhumaydhi FA, Wilairatana P (2022) Exploring the journey of emodin as a potential neuroprotective agent: novel therapeutic insights with molecular mechanism of action. Biomed Pharmacother 149:112877","journal-title":"Biomed Pharmacother"},{"key":"4762_CR81","doi-asserted-by":"publisher","unstructured":"Li Z, Bi H, Jiang H, Song J, Meng Q, Zhang Y, Fei X (2021) Neuroprotective effect of emodin against Alzheimer's disease via Nrf2 signaling in U251 cells and APP\/PS1 mice. Mol Med Rep 23(2):1. https:\/\/doi.org\/10.3892\/mmr.2023.12994","DOI":"10.3892\/mmr.2023.12994"},{"key":"4762_CR82","doi-asserted-by":"publisher","unstructured":"Dietrich M, Hecker C, Nasiri M et al (2021) Neuroprotective properties of dimethyl fumarate measured by optical coherence tomography in non-inflammatory animal models. Front Neurol 11. https:\/\/doi.org\/10.3389\/FNEUR.2020.601628\/FULL","DOI":"10.3389\/FNEUR.2020.601628\/FULL"},{"key":"4762_CR83","doi-asserted-by":"publisher","unstructured":"Awogbindin I, Onasanwo S, Ezekiel O et al (2021) Neuroprotection of kolaviron by regulation of nuclear factor erythroid 2-related factor 2 in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mice model of Parkinson. AJBPS. https:\/\/doi.org\/10.25259\/AJBPS_8_2021","DOI":"10.25259\/AJBPS_8_2021"},{"key":"4762_CR84","doi-asserted-by":"publisher","unstructured":"Lambert LJ, Muzumdar MD, Rideout WM, Jacks T (2017) Basic mouse methods for clinician researchers: harnessing the mouse for biomedical research. In: Basic Science Methods for Clinical Researchers, pp 291\u2013312. https:\/\/doi.org\/10.1016\/B978-0-12-803077-6.00014-X","DOI":"10.1016\/B978-0-12-803077-6.00014-X"},{"key":"4762_CR85","doi-asserted-by":"publisher","unstructured":"Chandrasekaran B, Al-Joubi H, Samarneh S et al (2020) Drug-receptor interactions. In: Frontiers in pharmacology of neurotransmitters, pp 31\u201368. https:\/\/doi.org\/10.1007\/978-981-15-3556-7_2","DOI":"10.1007\/978-981-15-3556-7_2"},{"key":"4762_CR86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/ACS.JPCB.3C05041","volume":"128","author":"M Ray","year":"2024","unstructured":"Ray M, Sayeed A, Ganshert M, Saha A (2024) Direct binding methods to measure receptor-ligand interactions. J Phys Chem B 128:3\u201319. https:\/\/doi.org\/10.1021\/ACS.JPCB.3C05041","journal-title":"J Phys Chem B"},{"key":"4762_CR87","doi-asserted-by":"publisher","first-page":"111376","DOI":"10.1016\/j.exger.2021.111376","volume":"150","author":"Y Hou","year":"2021","unstructured":"Hou Y, Li X, Liu C, Zhang M, Zhang X, Ge S, Zhao L (2021) Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson\u2019s disease. Exp Gerontol 150:111376. https:\/\/doi.org\/10.1016\/j.exger.2021.111376","journal-title":"Exp Gerontol"},{"key":"4762_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40168-020-00988-6","volume":"9","author":"YF Hou","year":"2021","unstructured":"Hou YF, Shan C, Zhuang SY, Zhuang QQ, Ghosh A, Zhu KC, Kong XK, Wang SM, Gong YL, Yang YY, Tao B (2021) Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson\u2019s disease. Microbiome 9:1\u20137. https:\/\/doi.org\/10.1186\/s40168-020-00988-6","journal-title":"Microbiome"},{"key":"4762_CR89","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/15376516.2020.1741053","volume":"30","author":"DX Wang","year":"2020","unstructured":"Wang DX, Di CA, Wang QJ et al (2020) Protective effect of metformin against rotenone-induced parkinsonism in mice. Toxicol Mech Methods 30:350\u2013357. https:\/\/doi.org\/10.1080\/15376516.2020.1741053","journal-title":"Toxicol Mech Methods"},{"issue":"9","key":"4762_CR90","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.3390\/ijms21093254","volume":"21","author":"I Miyazaki","year":"2020","unstructured":"Miyazaki I, Isooka N, Imafuku F, Sun J, Kikuoka R, Furukawa C, Asanuma M (2020) Chronic systemic exposure to low-dose rotenone induced central and peripheral neuropathology and motor deficits in mice: reproducible animal model of Parkinson\u2019s disease. Int J Mol Sci 21(9):3254. https:\/\/doi.org\/10.3390\/ijms21093254","journal-title":"Int J Mol Sci"},{"key":"4762_CR91","doi-asserted-by":"publisher","first-page":"2112146","DOI":"10.1155\/2022\/2112146","volume":"2022","author":"Y Ma","year":"2022","unstructured":"Ma Y, Rong Q (2022) Effect of different MPTP administration intervals on mouse models of Parkinson\u2019s disease. Contrast Media Mol Imaging 2022:2112146. https:\/\/doi.org\/10.1155\/2022\/2112146","journal-title":"Contrast Media Mol Imaging"},{"key":"4762_CR92","unstructured":"Barry MJ (2020) Rotational behavior during the pole test: a novel behavioral assay in a mouse model of Parkinson\u2019s disease.\u00a0PhD Dissertation, Texas A&M University, College Station Texas, USA"},{"issue":"1","key":"4762_CR93","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.1038\/s41598-022-14823-5","volume":"12","author":"YH Leem","year":"2022","unstructured":"Leem YH, Park JS, Park JE, Kim DY, Kim HS (2022) Neurogenic effects of rotarod walking exercise in subventricular zone, subgranular zone, and substantia nigra in MPTP-induced Parkinson\u2019s disease mice. Sci Rep 12(1):10544","journal-title":"Sci Rep"},{"key":"4762_CR94","doi-asserted-by":"publisher","first-page":"307","DOI":"10.31083\/J.JIN2002030\/HTM","volume":"20","author":"M Wada","year":"2021","unstructured":"Wada M, Ang MJ, Weerasinghe-Mudiyanselage PDE et al (2021) Behavioral characterization in MPTP\/p mouse model of Parkinson\u2019s disease. J Integr Neurosci 20:307\u2013320. https:\/\/doi.org\/10.31083\/J.JIN2002030\/HTM","journal-title":"J Integr Neurosci"},{"key":"4762_CR95","doi-asserted-by":"publisher","first-page":"122171","DOI":"10.1016\/j.lfs.2023.122171","volume":"333","author":"Y He","year":"2023","unstructured":"He Y, Zhao J, Dong H, Zhang X, Duan Y, Ma Y, Yu M, Fei J, Huang F (2023) TLR2 deficiency is beneficial at the late phase in MPTP-induced Parkinson\u2019s disease mice. Life Sci 333:122171. https:\/\/doi.org\/10.1016\/j.lfs.2023.122171","journal-title":"Life Sci"},{"issue":"4","key":"4762_CR96","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1109\/TNSRE.2020.2971901","volume":"28","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Zhao Z, Wang Z, Wang X, Yan J, Li X (2020) The effect of low-intensity transcranial ultrasound stimulation on behavior in a mouse model of Parkinson\u2019s disease induced by MPTP. IEEE Trans Neural Syst Rehabil Eng 28(4):1017\u20131021. https:\/\/doi.org\/10.1109\/TNSRE.2020.2971901","journal-title":"IEEE Trans Neural Syst Rehabil Eng"},{"key":"4762_CR97","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/S12035-018-1020-1","volume":"56","author":"MG Jo","year":"2019","unstructured":"Jo MG, Ikram M, Jo MH et al (2019) Gintonin mitigates MPTP-induced loss of nigrostriatal dopaminergic neurons and accumulation of \u03b1-synuclein via the Nrf2\/HO-1 pathway. Mol Neurobiol 56:39\u201355. https:\/\/doi.org\/10.1007\/S12035-018-1020-1","journal-title":"Mol Neurobiol"},{"key":"4762_CR98","doi-asserted-by":"publisher","first-page":"12206","DOI":"10.1038\/s41598-017-08396-x","volume":"7","author":"N Abid","year":"2017","unstructured":"Abid N, Yoon G, Kim MO (2017) Molecular cloning and expression of osmotin in a baculovirus-insect system: purified osmotin mitigates amyloid-beta deposition in neuronal cells. Sci Rep 7:12206. https:\/\/doi.org\/10.1038\/s41598-017-08396-x","journal-title":"Sci Rep"},{"key":"4762_CR99","doi-asserted-by":"publisher","first-page":"8346","DOI":"10.1007\/S12035-018-1006-Z","volume":"55","author":"L Liu","year":"2018","unstructured":"Liu L, Fujimoto M, Nakano F et al (2018) Deficiency of tenascin-C alleviates neuronal apoptosis and neuroinflammation after experimental subarachnoid hemorrhage in mice. Mol Neurobiol 55:8346\u20138354. https:\/\/doi.org\/10.1007\/S12035-018-1006-Z","journal-title":"Mol Neurobiol"},{"key":"4762_CR100","doi-asserted-by":"publisher","first-page":"113608","DOI":"10.1016\/j.ab.2020.113608","volume":"593","author":"L Pillai-Kastoori","year":"2020","unstructured":"Pillai-Kastoori L, Schutz-Geschwender AR, Harford JA (2020) A systematic approach to quantitative Western blot analysis. Anal Biochem 593:113608. https:\/\/doi.org\/10.1016\/j.ab.2020.113608","journal-title":"Anal Biochem"},{"key":"4762_CR101","doi-asserted-by":"publisher","unstructured":"Ferrucci M, Fornai F (2021) MPTP neurotoxicity: actions, mechanisms, and animal modeling of Parkinson\u2019s disease. In: Handbook of neurotoxicity. Springer International Publishing, Cham, pp. 1\u201341. https:\/\/doi.org\/10.1007\/978-3-030-55535-9_36","DOI":"10.1007\/978-3-030-55535-9_36"},{"issue":"8","key":"4762_CR102","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/antiox9080743","volume":"9","author":"DS Simpson","year":"2020","unstructured":"Simpson DS, Oliver PL (2020) ROS generation in microglia: understanding oxidative stress and inflammation in neurodegenerative disease. Antioxidants 9(8):743. https:\/\/doi.org\/10.3390\/antiox9080743","journal-title":"Antioxidants"},{"issue":"s1","key":"4762_CR103","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.3233\/JAD-201074","volume":"82","author":"A Merelli","year":"2021","unstructured":"Merelli A, Repetto M, Lazarowski A, Auzmendi J (2021) Hypoxia, oxidative stress, and inflammation: three faces of neurodegenerative diseases. J Alzheimers Dis 82(s1):S109\u2013S126. https:\/\/doi.org\/10.3233\/JAD-201074","journal-title":"J Alzheimers Dis"},{"key":"4762_CR104","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.3390\/ijms23115938","volume":"23","author":"L Speranza","year":"2022","unstructured":"Speranza L, Angelo CD, Teleanu DM et al (2022) An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases. Int J Mol Sci 23:5938. https:\/\/doi.org\/10.3390\/ijms23115938","journal-title":"Int J Mol Sci"},{"key":"4762_CR105","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.3390\/molecules27103194","volume":"27","author":"A Rauf","year":"2022","unstructured":"Rauf A, Badoni H, Abu-Izneid T et al (2022) Neuroinflammatory markers: key indicators in the pathology of neurodegenerative diseases. Molecules 27:3194. https:\/\/doi.org\/10.3390\/molecules27103194","journal-title":"Molecules"},{"key":"4762_CR106","doi-asserted-by":"publisher","unstructured":"Mustapha M (2021) MPTP-induced mouse model of Parkinson\u2019s disease: a promising direction for therapeutic strategies. J Basic Med Sci 21(4):422\u2013433. https:\/\/doi.org\/10.17305\/bjbms.2020.5181","DOI":"10.17305\/bjbms.2020.5181"},{"key":"4762_CR107","doi-asserted-by":"publisher","unstructured":"Goyal A, Murti Y, Bhushan B et al (2021) A comprehensive review on therapeutic potential of a natural anthraquinone derivative emodin in brain-related disorders. Ingenta Connect. Curr Drug Targets 24(12):945\u2013958. https:\/\/doi.org\/10.2174\/1389450124666230818092506","DOI":"10.2174\/1389450124666230818092506"},{"key":"4762_CR108","doi-asserted-by":"publisher","unstructured":"Li R, Liu W, Ou L et al (2020) Emodin alleviates hydrogen peroxide-induced inflammation and oxidative stress via mitochondrial dysfunction by inhibiting the PI3K\/mTOR\/GSK3\u03b2 pathway in neuroblastoma SH-SY5Y cells. Biomed Res Int:1562915. https:\/\/doi.org\/10.1155\/2020\/1562915","DOI":"10.1155\/2020\/1562915"},{"key":"4762_CR109","doi-asserted-by":"publisher","first-page":"149688","DOI":"10.1016\/j.bbrc.2024.149688","volume":"704","author":"P Wu","year":"2024","unstructured":"Wu P, Xiao Y, Qing L, Mi Y, Tang J, Cao Z, Huang C (2024) Emodin activates autophagy to suppress oxidative stress and pyroptosis via mTOR-ULK1 signaling pathway and promotes multi-territory perforator flap survival. Biochem Biophys Res Commun 704:149688. https:\/\/doi.org\/10.1016\/j.bbrc.2024.149688","journal-title":"Biochem Biophys Res Commun"},{"key":"4762_CR110","doi-asserted-by":"publisher","first-page":"48","DOI":"10.31083\/J.JIN2202048","volume":"22","author":"W Jiang","year":"2023","unstructured":"Jiang W, Liu Z, Wu S et al (2023) Neuroprotection of emodin by inhibition of microglial NLRP3 inflammasome-mediated pyroptosis. J Integr Neurosci 22:48. https:\/\/doi.org\/10.31083\/J.JIN2202048","journal-title":"J Integr Neurosci"},{"key":"4762_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115512","author":"S Park","year":"2023","unstructured":"Park S, Jin M, Kang N et al (2023) Anti-inflammatory effects of novel Polygonum multiflorum compound via inhibiting P-NF-\u03baB\/MAPK and upregulating the Nrf2 pathways in LPS-stimulated microglia. Biochem Pharmacol. https:\/\/doi.org\/10.1016\/j.bcp.2023.115512","journal-title":"Biochem Pharmacol"},{"key":"4762_CR112","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/S10753-021-01581-1","volume":"45","author":"Y Liu","year":"2022","unstructured":"Liu Y, Shang L, Zhou J et al (2022) Emodin attenuates LPS-induced acute lung injury by inhibiting NLRP3 inflammasome-dependent pyroptosis signaling pathway in vitro and in vivo. Inflammation 45:753\u2013767. https:\/\/doi.org\/10.1007\/S10753-021-01581-1","journal-title":"Inflammation"},{"key":"4762_CR113","doi-asserted-by":"publisher","first-page":"101207","DOI":"10.1016\/j.arr.2021.101207","volume":"65","author":"W Zhang","year":"2021","unstructured":"Zhang W, Feng C, Jiang H (2021) Novel target for treating Alzheimer\u2019s diseases: crosstalk between the Nrf2 pathway and autophagy. Ageing Res Rev 65:101207. https:\/\/doi.org\/10.1016\/j.arr.2021.101207","journal-title":"Ageing Res Rev"},{"issue":"22","key":"4762_CR114","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.3390\/molecules25225474","volume":"25","author":"S Saha","year":"2020","unstructured":"Saha S, Buttari B, Panieri E, Profumo E, Saso L (2020) An overview of Nrf2 signaling pathway and its role in inflammation. Molecules 25(22):5474. https:\/\/doi.org\/10.3390\/molecules25225474","journal-title":"Molecules"},{"key":"4762_CR115","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/S12993-020-00171-9","volume":"16","author":"DM Monir","year":"2020","unstructured":"Monir DM, Mahmoud ME, Ahmed OG et al (2020) Forced exercise activates the Nrf2 pathway in the striatum and ameliorates motor and behavioral manifestations of Parkinson\u2019s disease in rotenone-treated rats. Behav Brain Funct 16:10. https:\/\/doi.org\/10.1186\/S12993-020-00171-9","journal-title":"Behav Brain Funct"},{"key":"4762_CR116","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/09727531211051976","volume":"28","author":"PC Tiwari","year":"2021","unstructured":"Tiwari PC, Chaudhary MJ, Pal R et al (2021) Pharmacological, biochemical and immunological studies on protective effect of mangiferin in 6-hydroxydopamine (6-OHDA)-induced Parkinson\u2019s disease in rats. J Chem Neuroanat 28:28\u201331. https:\/\/doi.org\/10.1177\/09727531211051976","journal-title":"J Chem Neuroanat"},{"key":"4762_CR117","doi-asserted-by":"publisher","first-page":"112756","DOI":"10.1016\/j.ejmech.2020.112756","volume":"207","author":"R Balakrishnan","year":"2021","unstructured":"Balakrishnan R, Azam S, Cho D-Y et al (2021) Natural phytochemicals as novel therapeutic strategies to prevent and treat Parkinson\u2019s disease: current knowledge and future perspectives. Eur J Med Chem 207:112756. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112756","journal-title":"Eur J Med Chem"},{"key":"4762_CR118","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jchemneu.2016.04.001","volume":"71","author":"SN Rai","year":"2016","unstructured":"Rai SN, Yadav SK, Singh D, Singh SP (2016) Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model. J Chem Neuroanat 71:41\u201349. https:\/\/doi.org\/10.1016\/j.jchemneu.2016.04.001","journal-title":"J Chem Neuroanat"},{"issue":"1","key":"4762_CR119","doi-asserted-by":"publisher","first-page":"40","DOI":"10.22376\/qual.sport.2023.9.1.40-45","volume":"9","author":"P J\u0119druszczak","year":"2023","unstructured":"J\u0119druszczak P, Zdun S, Walczak K, Weso\u0142owska Z, Gawe\u0142 W (2023) Ashwagandha (Withania somnifera)\u2014influence on sleep. Qual Sport 9(1):40\u201345. https:\/\/doi.org\/10.22376\/qual.sport.2023.9.1.40-45","journal-title":"Qual Sport"},{"key":"4762_CR120","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fphar.2022.837267","volume":"13","author":"XX Yang","year":"2022","unstructured":"Yang XX, Yang R, Zhang F (2022) Role of Nrf2 in Parkinson\u2019s disease: toward new perspectives. Front Pharmacol 13:123. https:\/\/doi.org\/10.3389\/fphar.2022.837267","journal-title":"Front Pharmacol"},{"key":"4762_CR121","doi-asserted-by":"publisher","first-page":"17223","DOI":"10.3390\/ijms24017223","volume":"24","author":"D Tonev","year":"2023","unstructured":"Tonev D, Momchilova A (2023) Oxidative stress and the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in multiple sclerosis: focus on certain exogenous and endogenous Nrf2 activators and therapeutic plasma exchange modulation. Int J Mol Sci 24:17223. https:\/\/doi.org\/10.3390\/ijms24017223","journal-title":"Int J Mol Sci"},{"key":"4762_CR122","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/antiox12030778","volume":"12","author":"R Amoroso","year":"2023","unstructured":"Amoroso R, Maccallini C, Bellezza I (2023) Activators of Nrf2 to counteract neurodegenerative diseases. Antioxidants 12:778. https:\/\/doi.org\/10.3390\/antiox12030778","journal-title":"Antioxidants"},{"key":"4762_CR123","doi-asserted-by":"publisher","unstructured":"Wang J, Cao Y, Lu Y et al (2023) Recent progress and applications of small molecule inhibitors of Keap1\u2013Nrf2 axis for neurodegenerative diseases. Eur J Med Chem 115998. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115998","DOI":"10.1016\/j.ejmech.2023.115998"},{"issue":"3","key":"4762_CR124","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/diseases11030089","volume":"11","author":"K Ramakrishna","year":"2023","unstructured":"Ramakrishna K, Nalla LV, Naresh D et al (2023) WNT-\u03b2 catenin signaling as a potential therapeutic target for neurodegenerative diseases: Curr. Status Future Perspect Dis 11(3):89. https:\/\/doi.org\/10.3390\/diseases11030089","journal-title":"Status Future Perspect Dis"},{"key":"4762_CR125","doi-asserted-by":"publisher","first-page":"101752","DOI":"10.1016\/j.jchemneu.2020.101752","volume":"104","author":"SN Rai","year":"2020","unstructured":"Rai SN, Singh P (2020) Advancement in the modelling and therapeutics of Parkinson\u2019s disease. J Chem Neuroanat 104:101752. https:\/\/doi.org\/10.1016\/j.jchemneu.2020.101752","journal-title":"J Chem Neuroanat"}],"updated-by":[{"DOI":"10.1007\/s12035-025-05091-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000}}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-04762-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-04762-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-04762-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:03:26Z","timestamp":1751378606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-04762-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":125,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["4762"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-04762-3","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version of this article, the beta actin in figure 3A is completely identical to 4A in the manuscript. Thus, these were corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12035-025-05091-1","URL":"https:\/\/doi.org\/10.1007\/s12035-025-05091-1","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal maintenance, treatments, behavioral studies, and surgical procedures were carried out according to the Animal Ethics Committee (IACUC) guidelines issued by Khyber Medical University. The experimental methods were carried out according to the approved guidelines, and all experimental protocols were approved by the animal ethics committee (IACUC) of the Khyber Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}